Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 in active lupus nephritis
2015-001750-15Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI 655064 in lupus nephritis (LN) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of patients with complete renal response. Started Mar 2016; status: completed.
02
Drugs
BI 655064
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2015-001750-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001750-15.